Posters & Publications

Scientific Paper

Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease

Ophthalmology and Therapy (April 2026) Nathan M Radcliffe, John Sheppard, Blake Simmons, Desiree Owen, Ashley Nguyen, Bill Cavanagh, Todd C Brady

Scientific Paper

Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber Trial

Ophthalmology Science (September 2025) Sumit Garg, Eric Donnenfeld, John Sheppard, Alice Epitropoulos, Todd C Brady

Scientific Paper

The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis

CLINICAL OPHTHALMOLOGY (December 2023) Christopher E. Starr, Kelly K. Nichols, Jacob R. Lang, Todd C Brady

Posters and Presentations

Poster Presentation – The Novel RASP Modulator Reproxalap Rapidly Improves Signs and Symptoms of Dry Eye Disease: The TRANQUILITY Run In Cohort

April 2022

Scientific Paper

Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial

Ophthalmology and Therapy (May 2022) Bill Cavanagh, Paul J. Gomes, Christopher E. Starr, Kelly K. Nichols, Todd C. Brady

Scientific Paper

Aldehyde Trapping by ADX-102 Is Protective against Cigarette Smoke and Alcohol Mediated Lung Cell Injury

Biomolecules (March 2022) Carmen A. Ochoa, Claire G. Nissen, Deanna D. Mosley, Christopher D. Bauer, Destiny L. Jordan, Kristina L. Bailey, Todd A. Wyatt

Scientific Paper

Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure

CLINICAL OPHTHALMOLOGY (January 2022) David Clark, Paul Karpecki, Anne Marie Salapatek, John D Sheppard, Todd C Brady

Scientific Paper

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

CLINICAL OPHTHALMOLOGY (September 2021) David McMullin, David Clark, Bill Cavanagh, Paul Karpecki, Todd C Brady

Scientific Paper

A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (May 2021) David Clark, John Sheppard, and Todd C. Brady

Scientific Paper

Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial

American Journal of Ophthalmology (May 2021) David Clark, Bill Cavanagh, Alan L. Shields, Paul Karpecki, John Sheppard, Todd C. Brady